This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Harvey, H. A. Articles by Members of The Central Pennsylvania Oncology Group, Search for Related Content PubMed PubMed Citation Articles by Harvey, H. A. Articles by Members of The Central Pennsylvania Oncology Group,

Cross-Over Comparison of Tamoxifen and Aminoglutethimide in Advanced Breast Cancer¹

Central Pennsylvania Oncology Group, The Milton S. Hershey Medical Center of The Pennsylvania State University, Hershey, Pennsylvania 17033 [H. A. H, A. L., D. S. W., R. J. S., A. E. B., R. J. D.], and Greater Baltimore Medical Center, Baltimore, Maryland 21233 [A. S. S.]

Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide. A similar group of 32 patients experienced a response rate of 28% when treated with tamoxifen first and a 19% objective response rate on subsequent therapy with aminoglutethimide. Patients who failed to respond to the first therapy seldom respodned on cross-over to the alternate therapy. Toxicities were acceptable with both forms of therapy. Tamoxifen and aminoglutethimide used sequentially are effective forms of palliative hormonal therapy in metastatic breast cancer.